Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2012

01.10.2012 | Epidemiology

Association of mammographic density with the proliferation marker Ki-67 in a cohort of patients with invasive breast cancer

verfasst von: Katharina Heusinger, Sebastian M. Jud, Lothar Häberle, Carolin C. Hack, Peter A. Fasching, Martina Meier-Meitinger, Michael P. Lux, Carsten Hagenbeck, Christian R. Loehberg, Thomas Wittenberg, Claudia Rauh, Florian Wagner, Michael Uder, Arndt Hartmann, Rüdiger Schulz-Wendtland, Matthias W. Beckmann, David L. Wachter

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

There is growing evidence that certain breast cancer (BC) risk factors specifically increase the risk for specific molecular tumor subtypes. Different molecular subtypes of BC can partly be described by analyzing proliferation in tumors. Very few data are available regarding the association of mammographic density (MD), as a BC risk factor, with proliferation. The aim of this study was to analyze the association between Ki-67 expression in BCs and MD. In this case-only study, data on BC risk factors, hormone receptor expression, and MD were available for 1,975 patients with incident BC. MD was assessed as percentage mammographic density (PMD) using a semiautomated method by two readers for every patient. The association of the Ki-67 proliferation index and PMD was studied using multifactorial analyses of covariance (ANCOVA), with PMD as the target variable and including well-known factors that are also associated with MD such as age, parity, use of hormone replacement therapy (HRT), and body mass index (BMI). There were no significant differences in PMD between women with BC who had low and high Ki-67 values (P = 0.31). However, there were relevant differences in women with low BMI (P = 0.07), and in women using postmenopausal HRT (P = 0.06) as well as in women with low PR values (P = 0.07). In these subgroups, the Ki-67 expression index increased with decreasing PMD. Likewise PMD is correlated with BMI, parity status, and menopausal status stronger in patients with low proliferating tumors, and with progesterone receptor expression in patients with high proliferating tumors. MD correlates inversely with Ki-67 proliferation in BC tumors only in some subgroups of BC patients, defined by commonly known BC risk factors that are usually associated with MD as well.
Literatur
4.
Zurück zum Zitat Dowsett M, Nielsen TO, A’Hern R et al (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103(22):1656–1664. doi:10.1093/jnci/djr393 PubMedCrossRef Dowsett M, Nielsen TO, A’Hern R et al (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103(22):1656–1664. doi:10.​1093/​jnci/​djr393 PubMedCrossRef
6.
Zurück zum Zitat Cuzick J, Dowsett M, Pineda S et al (2011) Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 29(32):4273–4278. doi:10.1200/JCO.2010.31.2835 PubMedCrossRef Cuzick J, Dowsett M, Pineda S et al (2011) Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 29(32):4273–4278. doi:10.​1200/​JCO.​2010.​31.​2835 PubMedCrossRef
10.
Zurück zum Zitat Phipps AI, Chlebowski RT, Prentice R et al (2011) Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst 103(6):470–477. doi:10.1093/jnci/djr030 PubMedCrossRef Phipps AI, Chlebowski RT, Prentice R et al (2011) Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst 103(6):470–477. doi:10.​1093/​jnci/​djr030 PubMedCrossRef
11.
Zurück zum Zitat Yang XR, Chang-Claude J, Goode EL et al (2011) Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 103(3):250–263. doi:10.1093/jnci/djq526 PubMedCrossRef Yang XR, Chang-Claude J, Goode EL et al (2011) Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 103(3):250–263. doi:10.​1093/​jnci/​djq526 PubMedCrossRef
12.
Zurück zum Zitat Stacey SN, Manolescu A, Sulem P et al (2008) Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 40(6):703–706. doi:10.1038/ng.131 PubMedCrossRef Stacey SN, Manolescu A, Sulem P et al (2008) Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 40(6):703–706. doi:10.​1038/​ng.​131 PubMedCrossRef
13.
Zurück zum Zitat Stacey SN, Manolescu A, Sulem P et al (2007) Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 39(7):865–869. doi:10.1038/ng2064 PubMedCrossRef Stacey SN, Manolescu A, Sulem P et al (2007) Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 39(7):865–869. doi:10.​1038/​ng2064 PubMedCrossRef
16.
Zurück zum Zitat Thomas G, Jacobs KB, Kraft P et al (2009) A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet 41(5):579–584. doi:10.1038/ng.353 PubMedCrossRef Thomas G, Jacobs KB, Kraft P et al (2009) A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet 41(5):579–584. doi:10.​1038/​ng.​353 PubMedCrossRef
17.
19.
Zurück zum Zitat Broeks A, Schmidt MK, Sherman ME et al (2011) Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet 20(16):3289–3303. doi:10.1093/hmg/ddr228 PubMedCrossRef Broeks A, Schmidt MK, Sherman ME et al (2011) Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet 20(16):3289–3303. doi:10.​1093/​hmg/​ddr228 PubMedCrossRef
20.
Zurück zum Zitat Antoniou AC, Beesley J, McGuffog L et al (2010) Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res 70(23):9742–9754. doi:10.1158/0008-5472.CAN-10-1907 PubMedCrossRef Antoniou AC, Beesley J, McGuffog L et al (2010) Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res 70(23):9742–9754. doi:10.​1158/​0008-5472.​CAN-10-1907 PubMedCrossRef
21.
Zurück zum Zitat Antoniou AC, Wang X, Fredericksen ZS et al (2010) A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet 42(10):885–892. doi:10.1038/ng.669 PubMedCrossRef Antoniou AC, Wang X, Fredericksen ZS et al (2010) A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet 42(10):885–892. doi:10.​1038/​ng.​669 PubMedCrossRef
26.
Zurück zum Zitat Yaghjyan L, Colditz GA, Collins LC et al (2011) Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics. J Natl Cancer Inst 103(15):1179–1189. doi:10.1093/jnci/djr225 PubMedCrossRef Yaghjyan L, Colditz GA, Collins LC et al (2011) Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics. J Natl Cancer Inst 103(15):1179–1189. doi:10.​1093/​jnci/​djr225 PubMedCrossRef
27.
Zurück zum Zitat Heusinger K, Jud SM, Haberle L et al (2012) Association of mammographic density with hormone receptors in invasive breast cancers—results from a case-only study. Int J Cancer. doi:10.1002/ijc.27515 Heusinger K, Jud SM, Haberle L et al (2012) Association of mammographic density with hormone receptors in invasive breast cancers—results from a case-only study. Int J Cancer. doi:10.​1002/​ijc.​27515
29.
30.
Zurück zum Zitat Beckmann MW, Brucker C, Hanf V et al (2011) Quality assured health care in certified breast centers and improvement of the prognosis of breast cancer patients. Onkologie 34(7):362–367. doi:10.1159/000329601 PubMedCrossRef Beckmann MW, Brucker C, Hanf V et al (2011) Quality assured health care in certified breast centers and improvement of the prognosis of breast cancer patients. Onkologie 34(7):362–367. doi:10.​1159/​000329601 PubMedCrossRef
31.
Zurück zum Zitat Ursin G, Astrahan MA, Salane M et al (1998) The detection of changes in mammographic densities. Cancer Epidemiol Biomarkers Prev 7(1):43–47PubMed Ursin G, Astrahan MA, Salane M et al (1998) The detection of changes in mammographic densities. Cancer Epidemiol Biomarkers Prev 7(1):43–47PubMed
Metadaten
Titel
Association of mammographic density with the proliferation marker Ki-67 in a cohort of patients with invasive breast cancer
verfasst von
Katharina Heusinger
Sebastian M. Jud
Lothar Häberle
Carolin C. Hack
Peter A. Fasching
Martina Meier-Meitinger
Michael P. Lux
Carsten Hagenbeck
Christian R. Loehberg
Thomas Wittenberg
Claudia Rauh
Florian Wagner
Michael Uder
Arndt Hartmann
Rüdiger Schulz-Wendtland
Matthias W. Beckmann
David L. Wachter
Publikationsdatum
01.10.2012
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2012
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-2221-3

Weitere Artikel der Ausgabe 3/2012

Breast Cancer Research and Treatment 3/2012 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.